Auricular neural stimulation as a new non-invasive treatment for opioid detoxification

Imran S. Qureshi1,2,3, Timir Datta-Chaudhuri3,4*, Kevin J. Tracey3,4, Valentin A. Pavlov3,4 and Andrew C. H. Chen1,3*

Abstract
The recent opioid crisis is one of the rising challenges in the history of modern health care. New and effective treatment modalities with less adverse effects to alleviate and manage this modern epidemic are critically needed. The FDA has recently approved two non-invasive electrical nerve stimulators for the adjunct treatment of symptoms of acute opioid withdrawal. These devices, placed behind the ear, stimulate certain cranial nerves with auricular projections. This neural stimulation reportedly generates a prompt effect in terms of alleviation of withdrawal symptoms resulting from acute discontinuation of opioid use. Current experimental evidence indicates that this type of non-invasive neural stimulation has excellent potential to supplement medication assisted treatment in opioid detoxification with lower side effects and increased adherence to treatment. Here, we review current findings supporting the use of non-invasive neural stimulation in detoxification from opioid use. We briefly outline the neurophysiology underlying this approach of auricular electrical neural stimulation and its role in enhancing medication assisted treatment in treating symptoms of opioid withdrawal. Considering the growing deleterious impact of addictive disorders on our society, further studies on this emerging treatment modality are warranted.

Keywords: Electrical nerve stimulation, Non-invasive intervention, COWS score, Addiction, Opioid epidemic, Auricular vagus nerve stimulation

Background
Approximately 36 million people are affected with opioid use disorder globally (Parrino et al. 2015). Opioid dependence is one of the emerging challenging public health issues across North America adversely impacting individual, social, and occupational functioning. Every day, more than 130 people in the United States alone die after overdosing on opioids (CDC/NCHS 2018). Recently, there has been a substantial increase in use and abuse of prescription opioids, illicit drugs, and synthetic opioids such as fentanyl (Parrino et al. 2015). The widespread availability of opioids and related medications coupled with inadequate education within the general population regarding its long-term consequences, and the potential for subsequent dependence, has immensely contributed to this epidemic. The misuse of and addiction to opioids, affects health as well as social and economic welfare; in 2013, the annual economic burden of opioid use disorder was nearly $80 billion, of which nearly $30 billion were due to healthcare costs (Florence et al. 2016).

Currently, there are three approved medications for the treatment of opioid addiction, including methadone, buprenorphine, and naltrexone (McElrath 2018; Maglione et al. 2018; Herring et al. 2019; Blanco and Volkow 2019) (Table 1). Buprenorphine, for example, has been quite effective in randomized clinical trials (Herring et al. 2019; Gowing et al. 2017) for managing acute symptoms during the detoxification and maintenance phases of opioid addiction treatment. However, despite the widespread availability of this medication, it is associated with significant undesirable symptoms of withdrawal during the initial course of treatment (Table 1). Naltrexone,
| Treatment       | Primary Mechanism of Action | FDA Approval Status | Pros                                                                 | Cons                                                                 |
|-----------------|----------------------------|--------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Buprenorphine   | Mu receptor partial agonist | Approved           | 1. Ceiling effect to prevent overdose.  
2. Prevents euphoria due to partial agonism therapy.  
3. Long-term injection formulation is available.  
4. Naloxone conjunction prevents misuse. | 1. Long term may lead to reduced libido.  
2. May cause nausea and constipation.  
3. Potential dependence on higher dosage. |
| Methadone       | Mu receptor full agonist   | Approved           | 1. Effective in resistant cases of opioid dependence.  
2. Effective in HIV and HCV infectious states  
3. Favorable prognostic outcome with history of non-compliance. | 1. Close supervision for its administration is required.  
2. More risk of sustaining dependence and GI related side effects.  
3. Increased risk of overdose if taken in conjunction with other controlled sedatives. |
| Naltrexone      | Mu receptor antagonist     | Approved           | 1. Effective in co-existing alcohol and opioid dependence.  
2. Prevents reinforcing effects of opioid use.  
3. Long-term injection formulation is available. | 1. Avoid in advanced liver diseases.  
2. Caution in those who have underlying severe depressive illness. |
| Lofexidine      | Alpha 2 receptor agonist   | Approved           | 1. Effective in withdrawal state driven by high sympathetic flow.  
2. Facilitates detoxification from opioids.  
3. First FDA approved non-opioid medication. | 1. May precipitate sedation, drowsiness.  
2. Blood pressure monitoring required - Risk of inducing hypotension. |
| Clonidine       | Alpha 2 receptor agonist   | Off label          | 1. Ameliorates withdrawal symptoms.  
2. Helps in alleviating anxiety and restlessness associated with withdrawal. | 1. Caution for sudden hypotension.  
2. Precipitates sedation and dizziness |
| Baclofen        | GABA-B receptor agonist    | Off label          | 1. Alleviates muscle spasms.  
2. Facilitates detoxification course through muscular symptom neutralization | 1. Abuse potential.  
2. Sedations, drowsiness and dizziness as part of side effects |
| Benzodiazepines | Increase effectiveness of GABA-A receptor complex | Off label | 1. Rapid relief of symptoms | 1. Highly addictive.  
2. Severe side effects including respiratory depression. |
| Neural Stimulation | Stimulation of V, VII, IX, X cranial nerves | Approved | 1. First FDA approved non systemic based device for alleviation of withdrawal symptoms.  
2. Reduces use of medications during acute withdrawal.  
3. Non-invasive, well tolerable, with no major side effects. | 1. Cost-effectiveness unknown  
2. Studies for long-term use are not available |

References:
- Gowing et al. 2017; Elkader and Sproule 2005
- Mattick et al. 2008; Eap et al. 2002; Bell and Strang 2020
- Blanco and Volkow 2019; Kleber 2007; Koehl et al. 2019
- McCambridge et al. 2007; Pergolizzi Jr. et al. 2019; Gerra et al. 2001; Kuszmaul et al. 2019
- Gerra et al. 2001; Kuszmaul et al. 2019
- Cousins et al. 2002; Rahimi-Movaghar et al. 2018
- Stein et al. 2016; Lintzeris and Nielsen 2010
- Miranda and Taca 2018; Baker and Chang 2016
similarly, helps maintenance of abstinence from opioids yet may worsen opioid withdrawal symptoms as naltrexone is an opioid antagonist. The Food and Drug Administration (FDA) recommends that individuals should be abstinent from opioid drugs for a week to 10 days before starting naltrexone (Blanco and Volkow 2019; Kleber 2007), leading to lower rates of naltrexone prescription for opioid abuse management.

Although symptoms of opioid withdrawal generally resolve after 5–14 days (depending on the half-life of the opioid), the distress in the first few days after abrupt discontinuation can be rather severe. Without adequate treatment, many patients are unable to complete opioid discontinuation (Mattick et al. 2008; Kosten and Baxter 2019) as avoidance of symptoms of opioid withdrawal often becomes the most powerful force driving continued use (Cicero and Ellis 2017). Besides buprenorphine and methadone, some supportive pharmacotherapeutic agents are available to mitigate uncomfortable symptoms associated with acute phase treatment including clonidine, baclofen, ibuprofen and lofexidine (Kleber 2007; Diaper et al. 2014). However, the overall effectiveness of the supportive medications is not satisfactory (Hermann et al. 2005). Furthermore, some medications used to manage acute opioid withdrawal are a subject of serious concerns. Benzodiazepines, for instance, are a commonly used class of medications (Stein et al. 2016), yet they can be additive and contribute to severe respiratory suppression and other side effects (Lintzeris and Nielsen 2010). Therefore, development of more efficient and with less side effects, pharmacological approaches for the treatment of opioid use disorder remains ongoing. Simultaneously, novel non-pharmacological interventions that can assist in treatment should also be explored.

Bioelectronic medicine is an emerging field exploring neuromodulation that provides alternative, non-pharmacological treatments for various diseases (Pavlov et al. 2019). Many of these therapeutic approaches are based on vagus nerve stimulation and have already generated promising results in several chronic disorders, including rheumatoid arthritis and inflammatory bowel disease (Koopman et al. 2016; Bonaz et al. 2016; Pavlov et al. 2019; Pavlov and Tracey 2017). The therapeutic utility of non-invasive approaches, including auricular vagus nerve stimulation, is also currently being explored (Miranda and Taca 2018). Recently, the U.S. Food and Drug Administration (FDA) has approved two devices for auricular stimulation intended to treat withdrawal symptom - “NSS-2 Bridge” developed by Innovative Health Solutions (I.H.S n.d.) and “Drug Relief” aural neurostimulator mobile health device, developed by DyAnsys (DyAnsys n.d.). The “NSS-2 Bridge” consists of electrodes placed on the ear which are connected to the “hearing aid” style body of the device, which is placed behind the ear (Fig. 1a). Electrical pulses are generated at the body of the device and are delivered to the ear via the electrodes. This device is indicated for use to help in alleviating withdrawal symptoms synergizing with acute pharmacotherapy during the detoxification phase (FDA 2017). The effects of this device have been related to reduction of autonomic symptoms associated with withdrawal from opioids including sweating, gastrointestinal upset, agitation, insomnia and joint pain (FDA 2017). The vagus nerve (cranial nerve X), trigeminal (V), facial

![Fig. 1a](source) The NSS-2 Bridge device placed on the ear. The body of the device is placed behind the ear. The stimulating electrodes are connected via wires and placed at key points on the ear. Each electrode contains a short penetrating needle which is used to provide percutaneous electrical stimulation. Source: Forbes.com: (source) b The DyAnsys Drug Relief stimulator place on the ear. The device is similar in construction to the NSS-2 Bridge device which served as the predicate for its approval. (source)
thetic activities while increasing parasympathetic activities (VII), and glossoharyngeal (IX) nerves have been proposed to mediate this type of response (Deuchars et al. 2018), suggesting the activation of the parasympathetic nervous system as the core basis of the device function. It has been shown that within 20 min of activation of this device, up to 62.7% reduction of withdrawal symptoms is appreciable, while 84.6% symptoms alleviation has been observed at the end of 60 min (Miranda and Taca 2018).

Here we summarize currently available information about the use of non-invasive device-generated auricular neuromodulation in the context of alleviating symptoms of opioid withdrawal.

Mechanisms of auricular neural stimulation for treatment of acute opioid withdrawal

The neurophysiological mechanisms underlying the beneficial effects of auricular stimulation in this context remain poorly understood. These non-invasive devices use stimulating electrodes that are attached percutaneously or transcutaneously to the distribution of peripheral afferent branches of cranial nerves. Animal studies have indicated that afferent neurons within the trigeminal, facial, glossoharyngeal and vagus nerves have projections to the brainstem, and primarily to the nucleus tractus solitarius (NTS) (Zhang and Ashwell 2001). The NTS then serves as a facilitator to relay the signals to higher brain areas including amygdala, hypothalamus and ventral medulla (Rinaman 2011; Pavlov et al. 2003). Functional MRI assessment of the effect of neural stimulation of the Cymba concha region of the external ear indicates activation of a brain network, consistent with previous findings about the brain distribution of afferent vagus nerve signaling (Frangos et al. 2015). This stimulation, compared with earlobe (control) stimulation, generates activation of the ipsilateral NTS, bilateral spinal trigeminal nucleus, dorsal raphe, locus coeruleus, and contralateral parabrachial area, amygdala, and nucleus accumbens (Frangos et al. 2015). These findings suggest possible brain mechanisms underly anti-convulsive, antidepressant and antinociceptive effects of tVNS or electrical VNS (via implanted devices) (Frangos et al. 2015). Neuromodulation through the amygdala is related to effects on emotional lability often seen during withdrawal phase of opioid dependence (Koop and Volkow 2010). Though there is a lack of long-term findings, the existing reports on the short-term use of auricular stimulation indicate of minimal reported side effects, limited to itching and local area redness in selected cases. This makes the approach a very useful and easy to use treatment modality during the acute phase of withdrawal management.

The mechanisms of action of these types of devices involve multiple domains. The main postulated pathophysiological basis revolves around reducing the sympathetic activities while increasing parasympathetic activities (Deuchars et al. 2018). Acute taVNS in healthy volunteers has been shown to increase heart rate variability, which is indicative for an increase vagus nerve activity to the heart, and to suppress sympathetic outflow (based on micro-neurography data) (Clancy et al. 2014). taVNS has also been shown to stimulate efferent vagus nerve signaling to the viscera as indicated by electromyography of the stomach and increased levels of gastrin (a surrogate marker for vagus nerve activation) in 14 patients requiring open laparotomy (Hong et al. 2019). These studies indicate that taVNS alters the balance between parasympathetic and sympathetic outflow, towards parasympathetic predominance, which can be beneficial in in many conditions characterized by increased sympathetic activity. This also should improve the balance between cholinergic and adrenergic signaling with relevance to the symptomatology in opioid withdrawal (Kosten and Baxter 2019; Brown et al. 1998; Baraban et al. 1995; Cecchi et al. 2007). Neural stimulation of these nerves normalizes autonomic dysfunction, which culminates in optimization of vital signs and acts as a synergistic mechanical intervention of gastrointestinal, cardiovascular and other systems (Deuchars et al. 2018; Browning and Travagli 2014). This subsequently ameliorates physical withdrawal symptoms such as sweating, muscular and abdominal cramps, diarrhea, joint pain, tremor, anxiety and so on with less or no medications needed (Deuchars et al. 2018; Waxenbaum and Varacallo 2019).

It is important to note that the effects of auricular neural stimulation may have a much broader scope and involve other mechanisms. Of specific interest is the possible effects of this neuromodulation on immune system components. Ongoing research during the last decade has significantly advanced our understanding of the molecular mechanisms at the interface between the nervous and immune systems (Pavlov and Tracey 2017; Chavan et al. 2017), which appear to play a role in addictions. There is a bi-directional neuro-immune communication, and neural pathways regulate immune function and inflammation (Pavlov et al. 2019; Pavlov and Tracey 2017; Terrando and Pavlov 2018). Greater understanding of these mechanisms has revealed possibilities in the use of targeted neuromodulation as a therapeutic approach for disorders involving immune dysregulation and inflammation (Pavlov et al. 2019) within the emerging field of bioelectronic medicine (Pavlov et al. 2019). Targeted neuromodulation through implanted and non-invasive devices is a core aspect of bioelectronic medicine (Pavlov et al. 2019; Addorioso et al. 2019). In addition to chronic inflammatory diseases, bioelectronic medicine has the potential to provide new treatments for many disorders and neuropsychiatric conditions, including chronic migraine, epilepsy, major depressive disorder, Alzheimer’s disease, rheumatoid arthritis, pre-diabetes, paralysis, gastrointestinal diseases, and even cancer (Pavlov and Tracey 2017; Miller et al. 2020).
Among all the available bioelectronic neuromodulatory approaches, auricular vagus nerve stimulation (aVNS) has been increasingly utilized because of its low cost, ease of application, and because it is non-invasive (Pavlov et al. 2019; Addorisi et al. 2019). The rationale for using aVNS on a specific target area of the ear (cymba concha) is based on anatomical studies suggesting that this area is the only place on the human body surface where there is afferent vagus nerve distribution (Mercante et al. 2018a; Mercante et al. 2018b). Therefore, direct stimulation of the afferent nerve fibers of the vagus nerve on the ear may be able to produce an effect similar to that produced by an implanted VNS device yet without the need for invasive surgical intervention. Evidence supporting this was recently demonstrated in a study where a form of transcutaneous auricular vagus nerve stimulation (taVNS) was applied in the treatment of rheumatoid arthritis (Addorisi et al. 2019), using mechanical stimulation of the ear. It was found that vibrotactile taVNS reduced whole-blood LPS-induced TNF production, and that the effect was sustained for a period of 24 h post stimulation. Though these findings are promising, as they indicate that taVNS can act in similar ways as VNS, an important follow up would be to combine taVNS with vagus nerve recording to better understand the neural circuits connecting the auricular branches to the cervical vagus nerve.

The effects of neural stimulation for the treatment of neuropsychiatric diseases, using taVNS or percutaneous auricular stimulation as used in the recently FDA approved devices, appear to be very similar to auricular acupuncture which has been widely used for substance use disorders (Chen et al. 2018; Baker and Chang 2016; Litscher 2019). Acupuncture has been shown to be effective for treating opioid withdrawal (Kaniusas et al. 2019; Mercante et al. 2018a; Mercante et al. 2018b; Chen et al. 2018). Studies indicate that acupuncture and electrical stimulation were more effective than medication and had fewer side effects such as insomnia, pain, and anxiety when used for treating withdrawal syndromes from acute discontinuation of opioids (Liu et al. 2009). In addition to promising clinical observations, animal studies have further explored the mechanisms of action for acupuncture in withdrawal treatment. For example, electro-acupuncture has been shown to reduce withdrawal behaviors in mice following abrupt discontinuation of morphine (Cheng et al. 1980) and to suppress naloxone-induced morphine withdrawal in rats (Fung et al. 1980). While the mechanisms of the widely used auricular acupuncture protocol are not fully understood, it is suggested that it works, at least in part, through regulation of the autonomic nervous system and immune responses (Kaniusas et al. 2019; Mercante et al. 2018b). Acupuncture needs to be administered by medical providers who have undergone specific training and special licensure, and who may be unavailable in acute detoxification units where patients receive treatment for acute opioid withdrawal. On the other hand, auricular nerve stimulation is easier to implement at these facilities.

**Transcutaneous neural stimulation as an adjunct treatment for acute opioid withdrawal**

As previously mentioned, auricular stimulation of certain cranial nerves helps in ameliorating autonomic symptoms in a very short span of time. For instance, it has been reported that neurostimulation using the NSS-2 Bridge device for 30 min resulted in at least 30% alleviation of autonomic symptoms associated with opioid withdrawal (FDA 2017).

The efficacy of the NSS-2 Bridge device has been supported by a recent retrospective study with 73 patients (Miranda and Taca 2018). The device was placed at the pre-auricular region with electrodes stimulating the auricular branches of cranial nerves. Patients were assessed based on severity of Clinical Opiate Withdrawal Scale (COWS) score (Tomkins et al. 2009; Wesson and Ling 2003). The mean COWS score of 20.1 (prior to use of the device) reportedly decreases to 7.5 following 20 min of nerve stimulation, and further down to 3.1, following 60 min (Miranda and Taca 2018). This is associated with a prompt and effective amelioration of withdrawal symptoms without any additional supportive pharmacotherapeutic intervention. The device remained in place for 5 days and 64 out of 73 patients returned to the clinic on day 5 to transition to medication-assisted treatment for maintenance of their abstinence using naltrexone.

Relatively recently, in June 2018, an additional auricular stimulation device, the “Drug Relief” aural neurostimulator mobile health device, developed by DyAnsys, also received FDA 510(k) premarket approval for patients dealing with opioid addictions (Fig. 1b). This approval cited the NSS-2 Bridge (approved via the de novo review pathway in November 2017) as a predicate device. Similar to NSS-2 Bridge, the Drug Relief wearable is a transcutaneous electrical nerve field stimulator, emitting electrical pulses through tiny needles into the nerves around the ear (https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K173861). This stimulation provides relief from symptoms associated with opioid withdrawal, including cravings, anxiety, agitation and depression. The device can be worn up to 5 days at a time, and company officials report that symptoms have eased within an hour of wearing the device.

Pain and emotional disturbances are common symptoms during opioid withdrawal. Of note, auricular neural stimulation had been used for chronic pain management with success in various health settings (e.g., reviewed in...
been utilized by practitioners with variable level of success as depicted in Table 1. Emotional disturbance such as major depression is a common neuropsychiatric ailment seen in clinical practice. Auricular acupuncture or neural stimulation has so far been associated with only minor local side effects at the device placement site. While this non-invasive modality appears to be an exciting new opportunity in alleviating the current opioid epidemic, more studies are clearly needed to further validate the potential of this intervention and support its use with the hope of helping our patients and their families.

Conclusion
Experimental evidence indicates that non-invasive device-generated auricular neural stimulation of certain cranial nerves, primarily vagus nerve, provides an innovative approach to alleviate opioid withdrawal symptoms. This approach may specifically help expedite the recovery phase during acute detoxification from opioids. This can ultimately reduce the need of supportive medications and can facilitate smooth transition from detoxification to commencing medication-assisted treatment in opioid-dependent patients. This treatment modality has so far been associated with only minor local side effects at the device placement site. While this non-invasive modality appears to be an exciting new opportunity in alleviating the current opioid epidemic, more studies are clearly needed to further validate the potential of this intervention and support its use with the hope of helping our patients and their families.

Abbreviations
FDA: Food and Drug Administration; COWS: Clinical Opiate Withdrawal Scale; NTS: Nucleus Tractus Solitarius; VNS: Vagus Nerve Stimulation; aVNS: auricular vagus nerve stimulation; taVNS: transcutaneous auricular vagus nerve stimulation

Acknowledgements
Not applicable.

Authors’ contributions
I.S.Q and A.C.H.C wrote the first draft of this review. T.D.C, V.A.P and K.J.T reviewed and edited the manuscript. All authors contributed to finalizing the manuscript for publication. The authors read and approved the final manuscript.

Funding
The work on this review was partially supported by NIH grants to K.J.T and V.A.P.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
A.C.H.C, I.S.Q, K.J.T, T.D.C, and V.A.P are employees of Northwell Health. K.J.T, T.D.C, and V.A.P are employees of the Feinstein Institutes for Medical Research. K.J.T is Editor in Chief of Bioelectronic Medicine. V.A.P is Executive Editor of Bioelectronic Medicine.

Author details
1Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA. 2Chemical Dependency Dual Diagnosis Outpatient Facility, Department of Psychiatry, Staten Island University Hospital, Northwell Health, Staten Island, NY, USA. 3Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA. 4Institute of Bioelectronic Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, USA.

Received: 22 January 2020 Accepted: 9 March 2020
Published online: 30 March 2020

References
Addisio M, Imperato GH, de Vos AF, Forti S, Goldstein RS, Pavlov VA, et al. Investigational treatment of rheumatoid arthritis with a vibrotactile device applied to the external ear. Bioelectron Med. 2019;5(1):1.
Baker TE, Chang G. The use of auricular acupuncture in opioid use disorder: a systematic literature review. Am J Addict. 2016;25(8):592–602.
Baraban SC, Stornetta RL, Guyenet PG. Effects of morphine and morphine withdrawal on adrenergic neurons of the rat rostral ventrolateral medulla. Brain Res. 1995;676(2):245–57.
Bell J, Strang J. Medication treatment of opioid use disorder. Biol Psychiatry. 2020; 87(1):82–8.
Blanco C, Volkow ND. Management of opioid use disorder in the USA: present status and future directions. Lancet. 2019;393(10182):1760–72.
Brown CH, Murphy NP, Munro G, Ludwig M, Bull PM, Leng G, et al. Interruption of central noradrenergic pathways and morphine withdrawal excitation of oxytocin neurones in the rat. J Physiol. 1998;507(Pt 3):831–42.
Browning KN, Travagli RA. Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Compr Physiol. 2014;4(4):1339–68.
Bonaz B, Sinniger V, Hoffmann D, Clarencon D, Mathieu N, Dantzer C, et al. Chronic vagus nerve stimulation in Crohn’s disease: a 6-month follow-up pilot study. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2016;28(6):948–53.
CDC/NCHS. Mortality. CDC WONDER. Atlanta: US Department of Health and Human Services, CDC. National Vital Statistics System; 2018.
Cecchi M, Capriles N, Watson SJ, Akil H. Beta1 adrenergic receptors in the bed nucleus of stria terminalis mediate differential responses to opiate withdrawal. Neuropsychopharmacology. 2007;32(3):589–99.
Chavan SS, Pavlov VA, Tracey KJ. Mechanisms and therapeutic relevance of neuro-immune communication. Immunity. 2017;46(6):927–42.
Chen Z, Wang Y, Wang R, Xie J, Ren Y. Efficacy of acupuncture for treating opioid use disorder in adults: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2018;2018:3724708.
Cheng RS, Pomeranz B, Yu G. Electroacupuncture treatment of morphine-dependent mice reduces signs of withdrawal, without showing cross-tolerance. Eur J Pharmacol. 1980;68(4):477–81.

Cicero TJ, Ellis MS. The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse. Dialogues Clin Neurosci. 2017;19(3):259–69.

Clancy JA, Mary DA, Witte KK, Greenwood JP, Deuchars SA, Deuchars J. Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nervous activity. Brain Stimul. 2014;7(6):871–7.

Cousins MS, Roberts DC, de Wint H. GABA(B) receptor agonists for the treatment of drug addiction: a review of recent findings. Drug Alcohol Depend. 2002;65(3):209–20.

Deuchars SA, Jall VK, Clancy J, Mahadi M, Murray A, Peers L, et al. Mechanisms underpinning sympathetic nervous activity and its modulation using transcutaneous vagus nerve stimulation. Exp Physiol. 2018;103(3):326–31.

Diaper AM, Law FD, Melchior JK. Pharmacological strategies for detoxification. Br J Clin Pharmacol. 2014;77(2):302–14.

DyAnys Drug Rel. Available from: https://www.dyansys.com/products-applications/products/drug-relief. Accessed 1 Feb 2020.

Eap CB, Buitlin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–93.

Eberhardson M, Tarnawski L, Centa M, Olofsson PS. Neural Control of Opioid Withdrawal: A New Concept. Frontiers in Pharmacology. 2016;7.

Esmaeili M. Pharmacological therapies for management of opium withdrawal symptoms. Addict Biol. 2005;10(2):165–70.

Frangos E, Ellrich J, Komisaruk B. Non-invasive access to the Vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. Brain Stimul. 2015;8(3):624–36.

Fung KP, Choa GH, Choy YM, Lee CY, Leung KC, Tsang D, et al. Effect of electroacupuncture on behavioral responses and plasma levels of ACTH and TSH in naloxone-injected morphine withdrawal in rats. Am J Chin Med. 1980;8(1–2):167–9.

Gera G, Zaimov A, Gusti F, Di Gennaro C, Zambelli U, Gardini S, et al. Loxefidine versus clonidine in rapid opiate detoxification. J Subst Abus Treat. 2002;21(1):11–7.

Gowing L, Ali R, White JM, Mbwede D. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev. 2017;2:CD002005.

Herrmann D, Klages E, Welzel H, Mann K, Croissant B. Low efficacy of non-opioid drugs in opioid withdrawal symptoms. Cochrane Database Syst Rev. 2017(11):1–7.

Hong GS, Zillekens A, Schneiker B, Pantelis D, de Jonge WJ, Schaefer N, et al. Non-invasive transcutaneous auricular vagus nerve stimulation prevents postoperative ileus and endotoxemia in mice. Neurogastroenterol Motil. 2019;31(13):e13501.

I.H.S. Bridge Device. Available from: https://i-h-s.com/products/bridge/. Accessed 1 Feb 2020.

Ju ZY, Wang K, Cui HS, Yao Y, Liu SM, Zhou J, et al. Acupuncture for neuropathic pain in adults. Cochrane Database Syst Rev. 2017;12:CD012057.

Kanussi J, Kampauch S, Tittgemeyer M, Panetos F, Gines RF, Papa M, et al. Current directions in the auricular Vagus nerve stimulation I - a physiological perspective. Front Neurosci. 2019;13:854.

Kleber HD. Pharmacologic treatments for opioid dependence: detoxification and maintenance options. Dialogues Clin Neurosci. 2007;9(4):455–70.

Koehler JA, Zimmerman DE, Bridgeman PJ. Medications for management of opioid use disorder. JAMA Health Pract. 2019;7(15):1097–103.

Koob GF, Volkow ND. Neurocircuitry of addiction. Neuropsychopharmacology. 2010;35(1):217–38.

Kosten TR, Baxter LE. Review article: effective management of opioid withdrawal symptoms: a gateway to opioid dependence treatment. Am J Addict. 2019;28(2):55–62.

Koopman FA, Chavan SS, Milijko S, Grado S, Sololovic S, Schuurman PR, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(20):2824–9.

Kou NZ, Chen H, Yu ML, Xu TC, Fu SP, Lu SF. Acupuncture for behavioral changes of experimental depressive disorder: a systematic review and meta-analysis. Sci Rep. 2017;7(1):9669.

Kuszmaul AK, Palmer EC, Frederick EK. Loxefidine versus clonidine for mitigation of opioid withdrawal symptoms: a systematic review. J Am Pharm Assoc. 2019;1(4):3043–4.

Linde K, Allais G, Brinkhaus B, Minder M, Vettock EA, et al. Acupuncture for the prevention of epidemic migraine. Cochrane Database Syst Rev. 2016(6):CD01218.

Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: interactions and clinical management. Am J Addict. 2010;19(1):59–72.

Litscher G. Ear Acupuncture according to the NADA (National Acupuncture Detoxification Association). Medicines (Basel). 2019;6(2):1–5.

Liu TT, Shi J, Epstein DH, Bao YP, Lu L. A meta-analysis of acupuncture combined with opioid receptor agonists for treatment of opiate-withdrawal symptoms. Cell Mol Neurobiol. 2009;29(4):449–54.

MacPherson H, Vertosick EA, Foster NE, Lewith G, Linde K, Sherren KJ, et al. The persistence of the effects of acupuncture after a course of treatment: a meta-analysis of patients with chronic pain. Pain. 2017;158(5):784–93.

Maglione MA, Raen L, Chen C, Azhar G, Shahindia N, Shen M, et al. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review. J Subst Abus Treat. 2018;89:28–51.

Manheimer E, Cheng K, Wieland LS, Shen X, Lao L, Guo M, et al. Acupuncture for hip osteoarthritis. Cochrane Database Syst Rev. 2018;5:CD001301.

Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Data Syst Rev. 2008;2:CD002207.

McCambridge J, Gossop M, Beswick T, Best D, Bearn J, Rees S, et al. Inpatient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, loxefidine + placebo, and methadone. Drug Alcohol Depend. 2007;88(1):91–5.

McElrath K. Medication-assisted treatment for opioid addiction in the United States: critique and commentary. Subst Use Misuse. 2018;53(2):334–43.

Mercante B, Deriu F, Rangon CM. Auricular Neuromodulation: The Emerging Concept beyond the Stimulation of Vagus and Trigeminal Nerves. Medicines (Basel). 2018;5(1):1–12.

Mercante B, Ginatempo F, Manca A, Meib F, Enrico P, Deriu F. Anatomico-physiologic basis for auricular stimulation. Med Acupunct. 2018a;30(3):141–50.

Miller L, Farajidavar A, Vegesna A. Use of Bioelectronics in the Gastrointestinal Tract. Cold Spring Harbor Perspect Med. 2019;9(9):1–15.

Miranda A, Taca A. Neuromodulation with percutaneous electrical nerve field stimulation is associated with reduction in signs and symptoms of opioid withdrawal: a multisite, retrospective assessment. Am J Drug Alcohol Abuse. 2018;44(5):56–63.

Parrino MW, Maremmani AG, Samuels PN, Maremmani I. Challenges and opportunities for the use of medications to treat opioid addiction in the United States and other nations of the world. J Addict Dis. 2015;34(2–3):255–62.

Pavlov VA, Chavan SS, Tracey KJ. Bioelectronic Medicine: From Preclinical Studies on the Inflammatory Reflex to New Approaches in Disease Diagnosis and Treatment. Cold Spring Harbor perspectives in medicine. 2020;10(3):1–15.

Pavlov VA, Tracey KJ. Neural regulation of immunity: molecular mechanisms and clinical translation. Nat Neurosci. 2017;20(2):156–66.

Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: a missing link in neuroinmunomodulation. Mol Med. 2003;8(5–6):125–34.

Pergolizzi JV Jr, Annabi H, Gharibo C, LeQuang JA. The role of Loxefidine in Management of Opioid Withdrawal. Pain Ther. 2019;8(1):67–78.

Rahimi-Movaghar A, Gholami J, Amato L, Hoseinie L, Yousef-Nooraei R, Amin-Esmaili M. Pharmacological therapies for management of opium withdrawal. Cochrane Database Syst Rev. 2018;6:CD007522.

Rinaman L. Hindbrain noradrenergic A2 neurons: diverse roles in autonomic, endocrine, cognitive, and behavioral functions. Am J Physiol Regul Integr Comp Physiol. 2011;300(2):R222–35.

Shiozawa P, Silva ME, Carvalho TC, Cordeiro Q, Brunoni AR, Fregni F. Transcutaneous vagus and trigeminal nerve stimulation for neuropsychiatric disorders: a systematic review. Arq Neuropsiquiatr. 2014;72(7):542–7.
Smith CA, Armour M, Lee MS, Wang LQ, Hay PJ. Acupuncture for depression. Cochrane Database Syst Rev. 2018;3:CD004046.

Stein MD, Kanabar M, Anderson BJ, Lemtlke A, Bailey GL. Reasons for benzodiazepine use among persons seeking opioid detoxification. J Subst Abus Treat. 2016;68:57–61.

Terrando N, Pavlov VA. Editorial: Neuro-immune interactions in inflammation and autoimmunity. Front Immunol. 2018;9:772.

Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the clinical opiate withdrawal scale (COWS) and single-item indices against the clinical institute narcotic assessment (CINA) opioid withdrawal instrument. Drug Alcohol Depend. 2009;105(1–2):154–9.

Waxenbaum JA, Varacallo M. Anatomy, Autonomic Nervous System. Treasure Island: StatPearls; 2019.

Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35(2):253–9.

Yeh CH, Chiang YC, Hoffman SL, Liang Z, Klem ML, Tam WW, et al. Efficacy of auricular therapy for pain management: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2014;2014:994670.

Zhang LL, Ashwell KW. The development of cranial nerve and visceral afferents to the nucleus of the solitary tract in the rat. Anat Embryol (Berl). 2001;204(2):135–51.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.